---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004904"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:12:07.172173+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

## Summary
- Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.
- Acquisition adds Neuraceq (florbetaben F18), an FDA-approved PET imaging agent for Alzheimer's disease diagnosis.
- Lantheus will assume up to $30M in seller's retained contingent liabilities under certain contractual arrangements.
- Transaction expected to close in H2 2025, subject to Life Healthcare shareholder vote, antitrust clearances, and SA Reserve Bank approval.
- Lantheus expects the deal to be accretive to adjusted EPS within 12 months of closing.

## SEC filing metadata
- accession: 0001193125-25-004904
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312525004904/0001193125-25-004904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312525004904/d860596d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004904
- JSON: https://secwatch.observer/filing/0001193125-25-004904.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.